News archive search
Search the Newsreel
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
- Showing
- 37–56
- Matches
- 56
- Sources here
- 12
- Companies here
- 2
Search results
Stored financial headlines
Active search
56 matching headlines
Ticker or company: OLMAMain company stories
Search results
Matching headlines
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Olema Pharmaceuticals (NASDAQ:OLMA) Downgraded by Wall Street Zen to "Strong Sell"
Wall Street Zen downgraded Olema Pharmaceuticals (NASDAQ:OLMA) to a "strong sell" from "sell," adding to mixed analyst opinions. Despite this, the overall analyst consensus remains a "Moderate Buy" with an average price target of $44.10, significantly above its current trading price of $11.70. The …
OLMA
main company
Sharemaestro market context
Price below Trend Line
52 weeks +84.5%
OLMA (NASDAQ: OLMA) insider plans Rule 144 sale of 12,500 common shares
Cyrus L. Harmon, an insider at Olema Pharmaceuticals, Inc. (NASDAQ: OLMA), has filed a Rule 144 notice to sell 12,500 common shares through Fidelity for an indicated value of $146,419.49 on July 24, 2026. This filing also discloses a prior sale of 12,500 common …
OLMA
main company
Sharemaestro market context
Price below Trend Line
52 weeks +84.5%
Siren L.L.C. Boosts Stake in Olema Pharmaceuticals, Inc. $OLMA
Siren L.L.C. significantly increased its stake in Olema Pharmaceuticals (NASDAQ:OLMA) during the first quarter, adding 1.46 million shares to hold a total of 4.76 million shares valued at about $70.9 million. Other institutional investors like Goldman Sachs and Geode Capital also raised their positions, …
OLMA
main company
Sharemaestro market context
Price below Trend Line
52 weeks +84.5%
Olema Pharmaceuticals, Inc. SEC Filing (Jul 23, 2026)
This article reports on an SEC Form 144 filing by Olema Pharmaceuticals, Inc. (OLMA) on July 23, 2026. The filing indicates a proposed sale of 12,500 common shares by a person affiliated with the issuer, acquired in 2007 as founder's shares. The aggregate market …
OLMA
main company
Sharemaestro market context
Price below Trend Line
52 weeks +84.5%
339,461 Shares in Olema Pharmaceuticals, Inc. $OLMA Bought by SEB Asset Management AB
SEB Asset Management AB has acquired 339,461 shares of Olema Pharmaceuticals (NASDAQ:OLMA) in the first quarter, representing a stake worth approximately $5.06 million and about 0.39% of the company. Institutional investors collectively own 91.78% of GLMA, indicating strong interest despite mixed analyst ratings. The …
OLMA
main company
Sharemaestro market context
Price below Trend Line
52 weeks +84.5%
Jennison Associates LLC Has $27.17 Million Stock Holdings in Olema Pharmaceuticals, Inc. $OLMA
Jennison Associates LLC significantly increased its stake in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) by 89.0% in the first quarter, now holding over 1.8 million shares valued at $27.17 million. This move is part of a broader trend of institutional investors and hedge funds acquiring substantial …
OLMA
main company
Sharemaestro market context
Price below Trend Line
52 weeks +84.5%
Olema Pharmaceuticals (NASDAQ:OLMA) Shares Up 5.9% - Here's Why
Olema Pharmaceuticals (NASDAQ:OLMA) saw its shares increase by 5.9% on Friday, trading at $11.7270 on lighter than usual volume. Analysts have a mixed but generally positive sentiment towards the stock, with a consensus "Moderate Buy" rating and a target price of $44.10. The company, …
OLMA
main company
Sharemaestro market context
Price below Trend Line
52 weeks +84.5%